Allergy Relief: Is There an Optimal Dose?
"Reanalyzing Immunotherapy Data for Personalized Treatment"
Allergic rhinoconjunctivitis, often accompanied by allergic asthma, affects many, leading to reliance on subcutaneous immunotherapy (SCIT). SCIT's effectiveness varies between different allergen immunotherapy (AIT) products, which aren't directly comparable due to differences in allergen content, structure, adjuvants, and formulations. As a result, each product requires individual efficacy documentation.
One such product, Alutard SQ Phleum pratense, used for grass pollen allergy, has demonstrated efficacy in adults and children in controlled clinical trials. These trials tested both the maximum maintenance dose of 100,000 SQ-U and a lower dose of 10,000 SQ-U. These studies highlight Alutard SQ Phleum pratense potential in allergy management.
Now, reanalyzing data from a large UK study (UK22) using a combined symptom and medication score (CSMS), provides new insights. This method, endorsed by the World Allergy Organization (WAO) and the European Academy of Allergy and Clinical Immunology (EAACI), offers a more comprehensive way to assess AIT efficacy by considering both symptom severity and medication use. This approach aims to standardize clinical endpoints in AIT trials, improving their quality and comparability.
Personalized Allergy Treatment
Allergen immunotherapy (AIT) is described as a model for tailored treatment because the agents causing allergic symptoms can be characterized at the molecular level. Personalized approaches have improved the precision of allergy diagnosis and may increase AIT effectiveness by better targeting treatment to its causes. A 2026 review notes that real-world use of AIT for IgE-mediated respiratory allergy is limited by access and adherence, and that long-term outcomes for telemedicine-enabled sublingual immunotherapy remain incompletely characterized.
Precision Treatment and Its Challenges
Allergen immunotherapy (AIT) is presented as a precision-medicine approach that links identification of a disease’s molecular mechanism and diagnostic tools with treatment directed at that mechanism. A review of personalized medicine in pediatric allergy identifies potential challenges including high health-care costs, greater complexity of therapy, the need for physician allergy expertise, and ethical and data-safety concerns. These considerations may complicate efforts to advance personalized allergy care.
The 1911 Beginnings of Immunotherapy
In 1911, Leonard Noon showed that repeated injections of crude grass-pollen extract reduced immediate conjunctival sensitivity to grass pollen in people with hay fever. This early work established a foundational approach to allergen immunotherapy. A historical account also names John Freeman alongside Noon in pioneering work using small, increasing doses of grass-pollen extract to reduce hay-fever symptoms.
Personalized Allergy Treatment: Finding the Right Dose
The reanalysis of the UK22 trial applied the combined symptom and medication score (CSMS) to data from patients receiving either a placebo, 10,000 SQ-U, or 100,000 SQ-U of Alutard SQ Phleum pratense. The CSMS considered nasal, eye, and lung symptoms, along with medication usage weighted by type (e.g., sodium cromoglicate, fluticasone nasal spray).
- The 100,000 SQ-U group saw a reduction of 2.47 score points (P < .0001), a 36.06% relative difference to placebo.
- The 10,000 SQ-U group experienced a reduction of 1.70 score points (P = .0098), a 24.85% relative difference to placebo.
- The differences between the two immunotherapy groups were not statistically significant.
Evidence, Outcomes, and Current Treatments
An Indonesia-based study of children with allergic rhinitis in private practice reported that lowering the combination symptom and medication score (CSMS) by 1.0 cost IDR 9,550,126.6 with subcutaneous allergen immunotherapy (SCIT), compared with IDR 52,073,938.9 without SCIT. A separate study evaluated immunotherapy efficacy using daily symptom score, daily medication score, and CSMS at least three months after treatment. A 2022 review states that numerous studies have confirmed allergen immunotherapy’s efficacy in the 110 years since Noon’s classical study, while a 2026 review describes subcutaneous and sublingual immunotherapies as standards of care for allergic rhinitis.
Variable Results in Immunotherapy
Although allergen immunotherapy’s efficacy and safety have been established in numerous randomized clinical trials, reported study results may vary substantially. A 2026 review identifies this variability as an important feature of the evidence on AIT. Another review describes AIT as gradually exposing the immune system to increasing allergen doses to promote desensitization and immune tolerance, while noting that its effects include altered antibody responses.
A Tailored Approach to Allergy Relief
This reanalysis supports the idea of a patient-individualized treatment schedule. Starting with a lower maintenance dose of 10,000 SQ-U, where clinical efficacy has been demonstrated, may be optimal. If symptoms persist during the grass pollen season, the dose could be increased to 100,000 SQ-U to achieve a greater clinical effect.
Personalization and Emerging Tools
A review of allergen immunotherapy for allergic rhinitis highlights current efforts to improve symptom control, safety, and adherence, including emerging approaches beyond established subcutaneous and sublingual immunotherapies. Another review identifies biologics and biomarkers as areas of current research in allergy management and allergen immunotherapy. A 2024 article describes potential uses of artificial intelligence, including allergen mapping, automated patient monitoring, and targeted immunotherapy, as part of more tailored allergy care.
New Directions in Food Allergy Care
A 2026 review of challenges in allergic diseases notes newer approaches to food allergy treatment, including oral immunotherapy and biologics for patients with immunoglobulin E (IgE)-mediated food allergies. It also mentions more recent personalized treatment for peanut allergy. These examples place individualized treatment within a broader landscape of evolving allergy care.
This approach could strike a balance between tolerability and clinical effectiveness. By carefully adjusting the dose based on individual responses, healthcare providers can potentially optimize outcomes for patients undergoing AIT.
Ultimately, personalized immunotherapy offers the potential to significantly improve the quality of life for individuals struggling with allergic rhinoconjunctivitis, paving the way for more effective and well-tolerated treatment strategies.